Possi bilities and perspectives of colchicine application in complex therapy in patients with COVID-19

The new coronavirus infection, which has become a pandemic, is greatly increasing interest in the search for new pharmacological drugs with antiviral and anti-infl ammatory properties. Colchicine, which has been used in medicine for centuries and has been mainly known as arthrifuge, has come to be unexpectedly considered as a drug aff ecting the cumulative endpoint in outpatients, including death and hospitalization requirement in a recent large, well-planned, randomized controlled trial. The article provides data on the pharmacodynamics of the drug, which consists in blockade of infl ammasome activation in patients with COVID-19, and an eff ective impact on the mechanisms of “cytokine storm” — a predictor of acute respiratory distress syndrome and sepsis as a major cause of multi-organ lesions and death. The information that its spectrum of anti-infl ammatory activity may explain the vasoprotective eff ects in patients with coronary heart disease (CHD) who underwent acute infarction in the COLCOT study, is particularly attractive from the point of view of the perspectives for the oral colchicine application in COVID-19. High tolerability of the drug, the absence of severe adverse reactions, simple dosing regimen, low cost of colchicine, the absence of signifi cant drug interactions are additional advantages. The authors of this article believe that this information is suffi cient for planning a study of the eff ectiveness of colchicine as an element of complex therapy in hospitalized patients with COVID-19 in combination with acute coronary syndrome, including the need for percutaneous coronary intervention. Early anti-infl ammatory therapy in patients with COVID-19 is still not recommended, despi te th e fact t h at there comes an understanding of its necessity. And in this situation, colchicine has the potential to challenge.

Colchicine in patients with coronary heart disease: new possibilities in reduction of the residual inflammatory risk

Inflammation plays an important role in atherosclerotic plaque destabilisation and the development of cardiovascular complications. Suppression of its activity in order to reduce residual inflammatory risk in atherosclerotic cardiovascular diseases remains an urgent and unresolved problem to the date. Over the recent years, evidence of the effectiveness of such an approach in secondary prevention of coronary heart disease has been obtained. The purpose of this review was to analyse modern literature on the effect of anti-inflammatory therapy with colchicine on the prognosis of patients with coronary heart disease. The review was carried out using the search for papers published in the PubMed and ClinicalTrials databases within the period from 2007 to 2021. The search was carried out using the keywords «colchicine», «inflammation», «atherosclerosis», «coronary heart disease» and «acute coronary syndrome». The anti-inflammatory and antiatherogenic effects of colchicine are discussed. The paper presents results of studies devoted to the use of colchicine in chronic and acute coronary syndrome, including the key ones LoDoCo2 (2020) and COLCOT (2019) which provided evidence of the effect of the drug on the disease outcome. The issues of safety and prospects of colchicine application in clinical practice for reduction of the residual inflammatory risk in patients with coronary heart disease are addressed.

Improving the Efficiency of Colchicine-Based Chromosomal Doubling of Maize Haploids

Production and use of doubled haploids (DH) is becoming an essential part of maize breeding programs worldwide as DH lines offer several advantages in line development and evaluation. One of the critical steps in maize DH line production is doubling the chromosomes of in vivo-derived haploids so that naturally sterile haploids become reproductively fertile diploids (DH) to produce seed. This step of artificially doubling the chromosomes is labor-intensive and costly; hence, optimizing protocols to improve the doubling success is critical for achieving efficiencies in the DH production pipelines. Immersion of 3–4-day old germinating haploid seedlings in colchicine solution is commonly used for chromosome doubling in large-scale maize DH line production. This manuscript presents a new method of colchicine application to haploid seedlings that showed superior doubling rates compared to other methods like standard seedling immersion, seed immersion, root immersion, and direct application of colchicine solution to the seedlings at V2 stage in the greenhouse trays. The new method involves immersing the crown region of the haploid seedlings along with all the seedling roots at V2 stage in the colchicine solution. Further experiments to optimize this method indicated that increasing colchicine concentration had a very positive effect on overall success rate in chromosomal doubling, while not drastically affecting survival rate. The optimized method showed on average 5.6 times higher overall success rate (OSR) compared to the standard haploid seedling immersion method which was the second-best method in our experiments. This improved method of colchicine application saves resources by reducing the number of haploids to be generated and handled in a maize DH production pipeline.